)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Nuwellis
Nuwellis (NUWE) investor relations material
Nuwellis Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor presentation summary25 Aug, 2026
Investment highlights
Aquadex ultrafiltration technology offers precise, predictable fluid removal, reducing readmissions and improving outcomes.
Platform expansion targets new indications and leverages partnerships to broaden cardiorenal solutions.
Addressable U.S. market opportunity exceeds $4.2 billion across five clinical segments.
Pediatric segment represents 50% of revenues, with adoption in leading children's hospitals.
1H26 revenue grew 20% year-over-year, with gross margins improving to 76%.
Clinical need and solution
Fluid overload is a major driver of mortality and hospital readmissions in critical care, heart failure, and pediatrics.
Aquadex provides low-volume ultrafiltration for controlled fluid removal when diuretics fail.
System is adopted in ICU, cardiac surgery, and pediatric critical care programs.
Technology enables precise, gentle fluid management, especially for low-weight pediatric patients.
Business model and commercial execution
Aquadex system generates high-margin recurring revenue through single-use disposables.
Flexible acquisition models include purchase, lease, or rental of capital equipment.
Broad clinical coverage with 29% pediatric, 28% critical care, and 27% heart failure segment growth in H1.
Active in ~135 hospital accounts, including top academic centers.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nuwellis
- Up to 1.35M shares offered via warrants, with proceeds for working capital amid ongoing losses.NUWE
Registration filing - Q2 2026 revenue up 14%, gross margin at 76%, net loss narrowed, but Nasdaq risks persist.NUWEQ2 2026
- Votes sought for warrant issuance, reverse split, and adjournment to support Nasdaq compliance.NUWEProxy filing
- Votes are sought for warrant share issuance, a reverse split, and meeting adjournment to maintain compliance.NUWEProxy filing
- Best-efforts offering targets $4.4M for working capital, with high dilution and ongoing losses.NUWERegistration filing
- Pediatric and critical care growth, innovation, and operational discipline drive revenue momentum.NUWEInvestor presentation
- Offering up to $4.4M in equity and warrants, with high dilution and operational risks.NUWERegistration filing
- Up to $4.4M sought via equity and warrants to fund operations amid high product and financial risk.NUWERegistration filing
- Revenue up 26% to $2.4M, gross margin 70.1%, net loss $4.5M, with new patents and capital needs.NUWEQ1 2026
Next Nuwellis earnings date
Q3 202612 Nov, 2026
Nuwellis
Next Nuwellis earnings date
Q3 202612 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Nuwellis, Inc. is a medical technology company that develops and provides innovative fluid management solutions for patients suffering from fluid overload. The company's primary product is an ultrafiltration system designed to remove excess fluid from patients in cases such as heart failure, kidney disease, and critical care conditions. Nuwellis serves hospitals and healthcare providers, focusing on improving patient outcomes through precise fluid management in both adult and pediatric care. The company is headquartered in Eden Prairie, United States, and its shares are listed on the NASDAQ.